Related Experiment Videos
Islet defects and insulin resistance in models of obese non-insulin-dependent diabetes
1Department of Pharmaceutical Sciences, Aston University, Birmingham, U.K.
Diabetes/Metabolism Reviews
|November 1, 1993
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future.
Clinical pharmacology and therapeutics·2015
Safety of antidiabetes medications: An update.
Clinical pharmacology and therapeutics·2015
Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
Diabetic medicine : a journal of the British Diabetic Association·2014
Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.
Diabetes, obesity & metabolism·2014
Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.
Diabetes, obesity & metabolism·2012
Islet transplantation: present and future perspectives.
Diabetes/metabolism reviews·1999
MHC restriction to T-cell autoaggression: an emerging understanding of IDDM pathogenesis.
Diabetes/metabolism reviews·1999
Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years.
Diabetes/metabolism reviews·1999
From oncogenesis to approval: the lentiviral gene therapy revolution in Wiskott-Aldrich syndrome.
Regenerative medicine·2026
Primary extranodal marginal zone lymphoma of gastric mucosa-associated lymphoid tissue in children: a case report and review of the literature.
Journal of medical case reports·2026
Beyond MYD88-only testing: MYD88/CD79B profiling improves molecular detection and MCD genotyping in VRL and CNS lymphomas.
Experimental hematology & oncology·2026
Geranylgeranylation is required for B-cell proliferation and plasma cell survival implications for autoimmune therapy.
Cellular & molecular immunology·2026
A microbiota-driven CCL25-CCR9 axis reprograms intestinal ILC2s in the distal small intestine to promote metabolic dysfunction in obesity.
Cellular and molecular gastroenterology and hepatology·2026